课题基金 / 基金详情

Implementation of a Novel Multi-Platform Evidence-Based Clinical Decision Support System

Implementation of a Novel Multi-Platform Evidence-Based Clinical Decision Support System
新型多平台循证临床决策支持系统的实施
批准号:
10175756
负责人:
THOMAS G MCGINN
金额:
$40.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-03-01 至 2022-06-30

项目摘要

项目成果

THOMAS G MCGINN的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要
英文摘要
Project Abstract Venous thromboembolism (VTE), consisting of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a deadly disease with 30-day and one-year case fatality in the general population of 14% and 29%, respectively. This concern has increased with the recent pandemic as complications due to VTE have been associated with 40% of deaths of patients with Coronavirus Disease 2019 (COVID-19). The overarching aim of this proposal is: 1) to refine and validate two clinical prediction rules (CPRs) for assessment of VTE in patients presenting to or admitted from the emergency department (ED) with COVID-19 and 2) to design, perform usability testing, and implement two clinical decision support (CDS) tools based on these CPRs within our novel, innovative service-oriented architecture (SOA)-based complex CDS system (CDSS). Wells’ criteria in combination with D-Dimer is a CPR that helps healthcare providers exclude PE and the need for unnecessary computed tomography pulmonary angiography (CTPA). In addition, acutely-ill hospitalized medical patients are at moderate-to-high risk for developing VTE events during the hospital stay. Hospitalized COVID-19 patients are at especially high risk of VTE, with recent reports suggest a prevalence of DVT as high as 46% in medical wards and PE as high as 42% in ICU settings. These data are consistent with VTE risk associated with previous viral pneumonias such as H1N1 which have shown a 23-fold increased risk for VTE. Thrombo-prophylaxis shows significant benefits for in-hospital period, but must be used appropriately as it carries risk for morbidity and mortality related to bleeding. VTE risk in admitted patients is difficult to assess and physicians rely on CPRs such as IMPROVE-D-Dimer (DD) for patient care. Our parent grant (1R18HS026196-01A1) proposed the use of two validated CPRs (Wells’ criteria and the IMPROVE model) within the context of a novel CDSS, building on a SOA that will function across multiple electronic health record (EHR) platforms. We will build upon our original idea by refining and validating the Wells’ criteria in the ED and IMPROVE-DD risk model in hospitalized COVID-19 patients and then implementing the CDS by utilizing the groundwork set forth within the platform we are currently developing for the parent grant. This work is significant because CPRs for VTE assessment are essential but have not been established or validated in COVID-19 patients. We are uniquely suited to perform this work at Northwell Health as we are at the forefront of fighting the pandemic, having treated over 150,000 COVID-19 patients with subsequent performance of high-level big data analysis on this cohort and are well positioned for appropriate validation and subsequent implementation of VTE risk assessment. The long-term goal of this project is implementation of evidence-based CDS tools on a widely disseminated platform to meaningfully inform universal VTE management of COVID-19 patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Spread the Word: Integrating Clinical Prediction Rules at the Point of Care
Spread the Word: Integrating Clinical Prediction Rules at the Point of Care
Spread the Word: Integrating Clinical Prediction Rules at the Point of Care
Evidence Based Decision Making: Integrating Clinical Prediction Rules into Electr
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: